First Patient Dosed in Clinical Trial of Soficitinib for Treating Vitiligo in China
InnoCare Pharma announces that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib, for the treatment of patients with non-segmental vitiligo in China.